Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 894 results for "ranbaxy industries"

Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner
India TV

Sun Pharma-Ranbaxy Laboratories deal comes under CCI scanner

Putting the multi-billion dollar Sun Pharmaceuticals Industries-Ranbaxy Laboratories deal under close scrutiny, fair trade watchdog CCI has sought more information from them to ascertain whether the deal would skew fair competition in pharma sector. India TV, 3 weeks ago
Sun-Ranbaxy deal under CCI scanner Times of India, 4 days ago
Concern over drug deal Calcutta Telegraph, 4 days ago

5 images for ranbaxy industries

India TV, 3 weeks ago, 1 month ago
India TV, 1 month ago
Financial Express, 1 month ago, 2 months ago

Sun Pharma-Ranbaxy deal in CCI crosshairs [Mint, New Delhi :: ]

July 30--NEW DELHI -- Sun Pharmaceutical Industries Ltd Officials at the competition body say it has issued so-called show-cause notices to both Ranbaxy and Sun Pharma. They add that they believe the deal could be against "national interest". None ...
 BusinessWeek1 month ago Sun Pharma-Ranbaxy CCI probe in new phase [Mint, New Delhi :: ]  BusinessWeek5 days ago Competition Commission extends Sun Pharma-Ranbaxy probe to new stage  Livemint.com5 days ago Sun Pharma, Cipla hit record highs as investors cheer June quarter earnings [Mint, New Delhi :: ]  BusinessWeek1 week ago

Here are top 10 stocks to keep an eye on August 25

Here are top 10 stocks to keep an eye on August 25 - Reliance Industries, Yes Bank, Maruti, Ranbaxy, Glenmark Pharma, United Brewries, United Spirits, Hindalco, JSPL and Kolte Patil.
 Money Control1 week ago Here are top 10 stocks to focus on August 22  Money Control1 week ago Stocks in news: Tilaknagar, United Spirits, Ranbaxy, MCF  Money Control1 week ago Stocks in news: ITC, LT, Bharti, Tata Steel, Ranbaxy, IDFC  Money Control1 month ago

Surround Sound: What Indian Pharma can learn from Ranbaxy's Texas case

There are important lessons for the Indian generic-drug industry in the case involving Ranbaxy Laboratories in the Texas Medicaid Fraud Prevention Act. According to recent reports, Ranbaxy could face a fine to the tune of Rs 240 crore in a case ...
 InToday1 week ago Review: Industrial infrastructure clusters in India  Money Control2 weeks ago Ranbaxy posts loss on provision for U.S. settlement  Yahoo! India1 month ago Ranbaxy Laboratories posts Rs185 crore loss in June quarter  Livemint.com1 month ago

Sun Pharma's Ranbaxy deal on course, hints at more acquisitions

Sun Pharmaceutical Industries, India's largest drugmaker by market value, said it is in the process of acquiring Ranbaxy Lab from Japan's Daiichi Sankyo, and is open for more acquisitions. "Till the time we are able to integrate Ranbaxy ...
 DNA India2 weeks ago Moody's upbeat on India pharma sector; Lupin, Ranbaxy, Cipla hit fresh 52-week high  Economic Times1 week ago Sun Pharma reports a strong quarter  Pharmacy Choice2 weeks ago Sun Pharma profit rises on US sales  Oman Tribune2 weeks ago
Down to Earth

Sun Pharma recalls 200 cancer drug vials from US

Second such recall this year by pharma giant that acquired Ranbaxy earlier this year Sun Pharmaceutical Industries Ltd has voluntarily recalled 200 vials of its cancer drug, gemcitabine, in the United States. This was because of lack of assurance of sterility ...
 Down to Earth1 month ago Too Big To Ignore  Businessworld India1 week ago Accumulate Sun Pharma; target of Rs 815: IIFL  Moneycontrol.com2 weeks ago No Signs of a Slowdown in Mergers  PharmTech.com1 month ago

Sun Pharma to seek shareholders approval for $4 billion acquisition of Ranbaxy

Sun Pharmaceutical Industries will be seeking shareholders approval for its $4 billion acquisition of Ranbaxy Laboratories in a court convened meeting at Vadodara on August 22, 2014. The Gujarat High Court had issued an order on July 16, directing ...
 Indian-Commodity1 month ago Ranbaxy Labs' court convened meeting on Sept 19, 2014  Money Control1 week ago Sun Pharma to seek shareholders nod for Ranbaxy acquisition  Business Standard1 month ago Sun Pharma to Seek Shareholders' Nod for Ranbaxy Acquisition  NDTV1 month ago

Sun Pharmaceutical Industries leads gainers in 'A' group

Ranbaxy Laboratories, Cipla, Jaypee Infratech and Aurobindo Pharma are among the other gainers. Shares of pharmaceutical companies dominated the gainers in the BSE's 'A' group. Drug maker Sun Pharmaceutical Industries jumped 4.64% to Rs 847.10. The stock ...
 Business Standard1 week ago

Ranbaxy's performance hinges on generic Diovan

Since Ranbaxy is being merged with Sun Pharmaceutical Industries, due by end 2014, an investment decision on the stock does not make sense. Photo: Pradeep Gaur/Mint Ranbaxy Laboratories Ltd posted a 50% increase in June quarter operating profit ...
 Livemint.com1 month ago Buy Lupin 1180 Call, says VK Sharma  Moneycontrol.com2 weeks ago Sun Pharma-Ranbaxy deal gets no-objection from BSE, NSE  Hindu Business Line1 month ago Ranbaxy-Sun Pharma deal gets nod from BSE, NSE  Indian-Commodity1 month ago

Ranbaxy brands to stay alive

Sun Pharmaceutical Industries has, in the wake of the acquisition of Ranbaxy Laboratories, prepared ambitious plans on research and development. A spokesman at Sun, largest pharma company in the country after the merger (and fifth largest ...
 Sify3 weeks ago Sun Pharma to retain Ranbaxy's brands in most markets  Smart Investor3 weeks ago Sun Pharma to retain Ranbaxy brands in most markets, US a grey area  Smart Investor3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less